Literature DB >> 33227229

Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.

Connie A Haley, Patricia Macias, Supriya Jasuja, Betsy A Jones, Marie-Claire Rowlinson, Roshni Jaimon, Pennelyn Onderko, Elaine Darnall, Maria E Gomez, Charles Peloquin, David Ashkin, Neela D Goswami.   

Abstract

The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.

Entities:  

Keywords:  BPaL; Nix-TB; United States; antimicrobial resistance; bacteria; bedaquiline; drug monitoring; linezolid; pretomanid; tuberculosis and other mycobacteria

Mesh：

Substances：

Year:  2020        PMID： 33227229      PMCID： PMC7774582          DOI： 10.3201/eid2701.203766

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN： 1080-6040            Impact factor:   6.883


  10 in total

Review 1.  The Role of Therapeutic Drug Monitoring in Mycobacterial Infections.

Authors:  Charles Peloquin
Journal:  Microbiol Spectr       Date:  2017-01

2.  Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.

Authors:  Francesca Conradie; Andreas H Diacon; Nosipho Ngubane; Pauline Howell; Daniel Everitt; Angela M Crook; Carl M Mendel; Erica Egizi; Joanna Moreira; Juliano Timm; Timothy D McHugh; Genevieve H Wills; Anna Bateson; Robert Hunt; Christo Van Niekerk; Mengchun Li; Morounfolu Olugbosi; Melvin Spigelman
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

3.  WHO global progress report on tuberculosis elimination.

Authors:  Emilia Harding
Journal:  Lancet Respir Med       Date:  2019-11-06       Impact factor: 30.700

4.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

5.  Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.

Authors:  Jian Xu; Bin Wang; Minghao Hu; Fengmin Huo; Shaochen Guo; Wei Jing; Eric Nuermberger; Yu Lu
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Authors:  Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

Review 7.  Pretomanid: First Approval.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2019-11       Impact factor: 9.546

8.  Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation.

Authors:  M Tobias Heinrichs; George L Drusano; David L Brown; Michael S Maynard; Sherwin K B Sy; Kenneth H Rand; Charles A Peloquin; Arnold Louie; Hartmut Derendorf
Journal:  Int J Antimicrob Agents       Date:  2018-10-29       Impact factor: 5.283

9.  Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.

Authors:  Taeksun Song; Myungsun Lee; Han-Seung Jeon; Yumi Park; Lori E Dodd; Véronique Dartois; Dean Follman; Jing Wang; Ying Cai; Lisa C Goldfeder; Kenneth N Olivier; Yingda Xie; Laura E Via; Sang Nae Cho; Clifton E Barry; Ray Y Chen
Journal:  EBioMedicine       Date:  2015-10-09       Impact factor: 8.143

10.  Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.

Authors:  Ashley N Brown; George L Drusano; Jonathan R Adams; Jaime L Rodriquez; Kalyani Jambunathan; Dodge L Baluya; David L Brown; Awewura Kwara; Jon C Mirsalis; Richard Hafner; Arnold Louie
Journal:  MBio       Date:  2015-11-03       Impact factor: 7.867
  10 in total
  3 in total

1.  In Vitro Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus.

Authors:  Olumide Martins; Jin Lee; Amit Kaushik; Nicole C Ammerman; Kelly E Dooley; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2021-09-13       Impact factor: 5.191

Review 2.  Diagnosis and treatment of tuberculosis in adults with HIV.

Authors:  Qiaoli Yang; Jinjin Han; Jingjing Shen; Xinsen Peng; Lurong Zhou; Xuejing Yin
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

Review 3.  Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.

Authors:  Stephani L Stancil; Fuad Mirzayev; Susan M Abdel-Rahman
Journal:  Drug Des Devel Ther       Date:  2021-06-28       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.